Brief: UK's NICE Says Benefits Of Alzheimer’S Treatment Lecanemab Too Small To Justify Cost To NHS

BioArctic AB

22/08/2024 10:00

Aug 22 (Reuters) - UK'S NICE: 
    * UK'S NICE: BENEFITS OF ALZHEIMER’S TREATMENT LECANEMAB ARE
TOO
SMALL TO JUSTIFY COST TO THE NHS
    * UK'S NICE: ISSUED DRAFT GUIDANCE FOR CONSULTATION NOT
RECOMMENDING LECANEMAB FOR USE ON NHS AS IT IS NOT COST
EFFECTIVE USE OF LIMITED NHS FUNDING

Source text for Eikon:  ID: 
Further company coverage:  4523.T 

 ((Reuters.Briefs@thomsonreuters.com;))